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Abstract 
Background and Purpose: 
Tiotropium bromide (TB) is a long acting muscarinic receptor antagonist used to manage 
chronic obstructive pulmonary disease (COPD). Recent meta-analyses suggest an 
increased risk of cardiovascular events with TB. Ca2+/calmodulin dependent kinase II 
(CaMKII) and L-type Ca2+ channels regulate Ca2+ concentrations allowing management of 
Ca2+ across membranes, however pathological increases are initially slow and progressive 
but once the cytosolic concentration rises >1-3 μM from ~100 nM, calcium overload occurs 
and can lead to cell death. Ipratropium bromide, a short acting muscarinic receptor 
antagonist has previously been found to induce Ca2+ mediated eryptosis. The aim of this 
study was to investigate the role of Ca2+ in Tiotropium bromide mediated cardiotoxicity. 
Experimental approach: 
Isolated Sprague-Dawley rat hearts were perfused with TB (10 – 0.1 nM) ± KN-93 (400 nM) 
or nifedipine (1 nM).  Hearts were stained to determine infarct size (%) using 
triphenyltetrazolium chloride (TTC), or snap frozen to determine p-CaMKII (Thr286) 
expression. Cardiomyocytes were isolated using a modified Langendorff perfusion and 
enzymatic dissociation before preparation for Fluo 3-AM staining and flow cytometric 
analysis. 
Key results: 
TB increased infarct size compared with controls by 6.91-8.41%, with no effect on 
haemodynamic function. KN-93/nifedipine with TB showed a 5.90/7.38% decrease in infarct 
size compared to TB alone, the combined use of KN-93 with TB also showed a significant 
increase in left ventricular developed pressure whilst nifedipine with TB showed a significant 
decrease in coronary flow. TB showed a 42.73% increase in p-CaMKII (Thr286) versus 
control, and increased Ca2+ fluorescence by 30.63% in cardiomyocytes.  
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Conclusions and implications: 
To our knowledge, this is the first pre-clinical study to show that Tiotropium bromide induces 
Ca2+ signalling via CaMKII and L-type Ca2+ channels to result in cell damage. This has 
significant clinical impact due to long term use of TB in COPD patients, and warrants 
assessment of cardiac drug safety.  
Keywords: Long acting muscarinic receptor antagonist; Cardiotoxicity; Tiotropium bromide; 
Calcium; Ca2+/Calmodulin kinase II (CaMKII) 
 
Abbreviations 
BPM Beats per minute  
CICR Ca2+ induced Ca2+ release  
CaMKII Ca2+/calmodulin dependent protein kinase II  
KRH Calcium free Krebs buffer  
DAG Diacylglycerol  
DMSO Dimethyl sulfoxide  
LSD Fisher's least significant difference  
IP3 Inositol 1,4,5 triphosphate  
IP3R IP3 receptor  
KH Krebs-Henseleit  
LDH Lactate dehydrogenase  
LVDP Left ventricular developed pressure  
SEM Mean standard error  
NCX Na+/Ca2+ exchanger  
-ve Negative 
Nif Nifedipine  
NO Nitric Oxide  
PIP2 Phosphatidylinositol 4,5 bisphosphate  
PLC Phospholipase C  
PVDF Polyvinylidene fluoride  
+ve Positive 
SR Sarcoplasmic reticulum  
SERCA Sarcoplasmic/endoplasmic reticulum Ca2+/ATPase  
TB Tiotropium bromide  
TTC Triphenyltetrazolium chloride  
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Introduction 
The importance of cellular calcium regulation is demonstrated in several processes such as 
excitability, cell motility and gene transcription; numerous sensor and adaptor proteins 
respond to changes in calcium concentrations and initiate cellular responses (Clapham, 
2007). Disturbances in calcium regulation can negatively affect cellular function and 
ultimately lead to cell death, best exemplified with compartmental dependence on calcium 
homeostasis, and its role in initiating cell death signalling (Orrenius et al., 2003). 
Calcium signalling is instrumental in the functioning heart and plays roles in contractility and 
gene transcription (Ronkainen et al., 2011). In cardiomyocytes, systole occurs via L-type 
Ca2+ channels, triggering Ca2+ induced Ca2+ release (CICR) via the sarcoplasmic reticulum 
(Bootman, 2012). Relaxation of cardiomyocytes occurs following Ca2+ removal via the 
Na+/Ca2+ exchanger (NCX), and the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase 
(SERCA) (Fearnley et al., 2011; Murphy & Steenbergen, 2008). The importance of 
intracellular calcium regulation is testified by the number of Ca2+ handling proteins involved 
in this process (e.g. calmodulin, calpains and Ca2+/calmodulin dependent protein kinase II 
(CaMKII)).  
Whilst calcium is necessary for cellular function, detrimental calcium influx can be linked to 
the dysfunction of several key channels. For example, sarcolemmal L-type calcium channels 
and SERCA dysfunction lead to hypercontracture and mitochondrial damage, resulting in cell 
death (Turer & Hill, 2010). In this context the ‘calcium hypothesis’ suggests that the cellular 
ability to regulate calcium is impaired following ischaemia, resulting in accumulation of toxic 
intracellular concentrations of Ca2+ through activation of the NCX, leading to mitochondrial 
dysfunction and apoptosis mediated cell death (Moens et al., 2005).  
Anti-muscarinics such as the long acting muscarinic receptor antagonist, Tiotropium bromide 
are used in the treatment of chronic obstructive pulmonary disease (COPD). However, a 
meta-analysis showed that cardiovascular risk, myocardial infarction and stroke were at 
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increased risk amongst COPD patients using anti-muscarinics (Singh et al., 2008). A recent 
clinical study also correlated the use of anti-muscarinics with adverse cardiovascular 
outcomes in patient trials (Liou et al., 2018), therefore indicating adverse cardiovascular 
effects with drug use. In particular, Ipratropium bromide, a short acting anti-muscarinic has 
been shown to exacerbate myocardial ischaemia/reperfusion injury in an in vitro whole heart 
model (Harvey et al., 2014) and initiate calcium mediated suicidal cell death of erythrocytes 
(Shaik et al., 2012), indicating the occurrence of intercellular signalling otherwise not 
ascribed to antagonists. 
In this study, we examine the role of Tiotropium bromide in Ca2+ mediated cardiotoxicity. 
Using whole heart rodent models, isolated cardiomyocytes and pharmacological inhibition of 
L-type Ca2+ channels and CaMKII, we investigate the effect of Tiotropium bromide on 
physiological calcium regulation and cellular signalling in the heart. 
 
Methods 
Animals and ethics 
Prior to experimentation, all studies were approved by the Coventry University Ethics 
committee (UK). Adult 3-month old male Sprague-Dawley rats (300g ± 50g body weight – 
Charles River, UK) were kept in humane conditions and fed a standard laboratory diet. 
Procedures were in accordance with the Guidelines on the Operation of the Animals 
(Scientific Procedures) Act 1986. Whole hearts were used for Langendorff models to record 
haemodynamic parameters and evaluate infarct development, tissue collection (Western 
blotting) and cardiomyocyte cell isolations. Group sizes were determined based on pilot data 
(data not shown) and as described by Harvey et al. (2014), all groups were designed to be 
equal, any loss in numbers were from experimental deviations. 
Whole heart Langendorff model and haemodynamic function 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
Animals were euthanised via cervical dislocation in accordance with the Schedule I Home 
Office procedure. Intact hearts were excised and immediately placed in ice cold Krebs-
Henseleit (KH - 118.5 mM NaCl, 25 mM NaHCO3, 12 mM Glucose, 4.8 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM MgSO4.7H2O and 1.7 mM CaCl2.2H2O) buffer before mounting onto the 
Langendorff apparatus, and retrogradely perfused with KH buffer (37oC, pH 7.4) saturated 
with 95% O2 and 5% CO2. Tiotropium bromide (10 nM – 0.1 nM) was examined at clinically 
relevant concentrations, with 1 nM subsequently used for all other studies along with KN-93 
(400 nM) and nifedipine (1 nM). Experimental protocols were as described by Gharanei et al. 
(2013). Haemodynamic parameters (coronary flow, heart rate and left ventricular developed 
pressure) were recorded at 5 minute intervals for the first 55 minutes and 15 minute intervals 
thereafter, using a physiological pressure transducer connected to a PowerLab (ADI, UK) 
and LabChart® software (v7). Controls received only Krebs-Henseleit (KH) buffer for the 
duration of the protocol (175 mins) with no drug intervention or protocol differences, all 
subsequent groups defined as ‘control’ or ‘normoxia’ followed this protocol [Supplementary 
File, S1]. For all drug groups (Tiotropium bromide, KN-93 and nifedipine), drug 
administration was initiated following 20 minutes of stabilisation and remained for the 
remainder of the protocol (155 minutes). Hearts were weighed at the end of the experimental 
protocol and stored at -20oC, before triphenyltetrazolium chloride (TTC) staining.  
Infarct size 
The TTC staining procedure was as previously described by Bell et al. (Bell, Mocanu, & 
Yellon, 2011). Frozen Langendorff hearts (-20oC) were sliced to obtain approximately 2 mm 
thick transverse slices and incubated in 1% TTC phosphate buffer (pH 7.4) at 37oC for 10 
minutes. Heart slices were then removed from the TTC buffer and placed in 10% formalin 
solution for a minimum of 4 hours prior to delineate viable and non-viable tissue. Viable 
tissue appeared red (tetrazolium positive) whilst infarcted areas appeared pale (tetrazolium 
negative) [Supplementary File, S2]. Areas of infarction were measured using ImageJ (NIH, 
Wisconsin, USA) by computerised planimetry to obtain an area percentage (infarct %). 
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Adult ventricular cardiomyocyte isolation 
Hearts were obtained as described above, and mounted onto a modified Langendorff set up 
perfused with a calcium free Krebs buffer (KRH - 119.9 mM NaCl, 5.4 mM KCl, 0.49 mM 
MgSO4, 10 mM Glucose, 19.98 mM Taurine, 5 mM Sodium Pyruvate, 5.06 mM Na2HPO4, 
11.76 mM KH2PO4 oxygenated with 95% O2 and 5% CO2, pH 7.4, 37
oC) via a mechanical 
pump set at a constant flow of 10 mls/min. Hearts were perfused for 3 minutes to ensure 
cessation of cardiac function before 5-7 minutes of perfusion with modified digestion buffer 
(KRH, 0.046% Gibco® Collagenase Type II, 34 μM CaCl2); during digestion, the coronary 
perfusate was collected and recycled throughout the 5-7 minute time period.  
Following enzymatic digestion, ventricular tissue was minced and aspirated for 5 minutes in 
digestion buffer for complete enzymatic dissociation, before filtration through nylon mesh. 
The filtrate was centrifuged (1200 RPM, 2 minutes) and the pellet was resuspended in 
restoration buffer composed of modified Krebs buffer (KRH, 5 mM Creatine, 50 μM CaCl2, 
1% BSA, 1% Pen/Strep) and maintained at 37oC; 3.4 μl of 1 M CaCl2 was added gradually to 
increase the calcium concentration to 1.13 M.  
Western blotting for phosphorylated CaMKIIThr286 
Left ventricular tissue was excised following Langendorff perfusion, and rapidly frozen in 
liquid nitrogen and stored at -80oC. Prior to use, frozen tissue were homogenised with lysis 
buffer (100 mM NaCl, 10 mM Tris base - pH 8.0, 1 mM EDTA - pH 8.0, 2 mM sodium 
pyrophosphate, 2 mM NaF, 2 mM β-glycerophosphate, SigmaFAST™ protease inhibitor 
cocktail tablets – 1 tablet/100ml and PhosStop™ - 1 tablet/10ml) and centrifuged (11000 
RPM, 10 minutes, 4oC) to obtain the supernatant. Protein content was calculated using the 
Pierce™ BCA assay kit (Thermo Fisher Scientific, UK). Samples were diluted to obtain a 
protein concentration of 50 μg using Laemmli buffer (250 mM Tris-HCl – pH 6.8, 10% 
glycerol, 0.006% bromophenol blue, 4% SDS, β-mercaptoethanol – pH 6.8) and incubated at 
100oC for 5 minutes. Samples were loaded and run using a Power-Pac 3000 (130-150V, 60-
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
75 minutes; Bio-Rad, UK), a semi-dry transfer system was used for protein transfer (PVDF 
Trans-Blot® Turbo™, mixed molecular weight transfer, 7 minutes; Bio-Rad, UK). PVDF blots 
were incubated in blocking buffer (5% w/v milk powder in Tris-buffered saline with 1% Tween 
20 - TBS/T, pH 7.4) for 60 minutes on an orbital shaker prior to overnight primary antibody 
incubation as instructed by the manufacturer (5% w/v bovine serum albumin (BSA) in TBS/T, 
4oC). Membranes were washed with TBS/T and incubated with secondary antibody in 
blocking solution (5% w/v milk powder in TBS/T, 1 hr) on an orbital shaker before 
visualisation using SuperSignal West Femto (Thermo Fisher Scientific, UK) and a ChemiDoc 
transluminator (Bio-Rad, UK) with ImageLab®. Membranes were auto-exposed to detect 
dense bands corresponding to the protein of interest. Images were captured and analysed 
by visual densitometry using ImageJ (NIH, USA). 
Calcium release measurement 
Fluo 3-AM (Life Technologies, UK) stock solution was reconstituted using DMSO (500 μM) 
and added to cardiomyocytes following incubation with Tiotropium bromide (1 nM) ± KN-93 
(400 nM), ionomycin (1 μM) as a positive control  and amiloride (100 mM) as a negative 
control, at a final concentration of 5 μM and incubated for 25 minutes, away from light. Cells 
were centrifuged (300 RPM, 2 minutes) and resuspended in fresh restoration buffer before 
incubation for de-esterification (10 minutes). Cells were immediately analysed using the FL-1 
channel of the flow cytometer (BD FACSCalibur, UK) at 488 nm excitation, set to count 
10,000 cells. All data points were normalised to the control group to account for background 
fluorescence. 
Statistical analysis 
Data presented in this study are expressed as the mean ± standard error of the mean 
(SEM). GraphPad Prism 7® and SPSS® v24 (IBM) software were used to statistically 
analyse the data. For haemodynamics and infarct data, one-way ANOVA with Tukey’s test 
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were used; cardiomyocyte data were analysed using ANOVA with Fisher’s Least Significant 
Difference (LSD) post-hoc test. A p-value of p<0.05 was considered statistically significant.  
Materials  
Tiotropium bromide (Sequoia Research Products Ltd, UK) was dissolved in Dimethyl 
sulfoxide (DMSO) (Sigma Aldrich, UK) before experimental use and diluted in Krebs 
Henseleit buffer for subsequent dilutions. 2,3,5-Triphenyltetrazolium Chloride (TTC) (Sigma 
Aldrich, UK) was used at a final concentration of 2%. KN-93 (CaMKII inhibitor), Nifedipine (L-
type Ca2+ channel blocker), Ionomycin (Ca2+ ionophore) and Amlodipine (L-type Ca2+ 
channel blocker) were purchased from Tocris (Bristol, UK) and dissolved in DMSO and 
stored at -20oC.  
Anti-CaMKII, p-CaMKII (Thr286) antibody and secondary HRP-linked anti-rabbit IgG were 
purchased from Cell Signaling, UK (Cell Signaling Technology Cat# 4436 and 3361). Mini-
PROTEAN® TGX™ pre-cast gels, the Mini-PROTEAN tetra cell, Trans-blot® Turbo™, and 
PVDF membranes were purchased from Bio-Rad Ltd. (UK).  
Results 
Effect of Tiotropium bromide on whole heart haemodynamic function and infarct size. 
Tiotropium bromide (TB) 0.1 nM showed an increase in coronary flow compared to TB 10 
nM at 70 minutes (109.34 ± 18.18% (TB 0.1 nM) vs. 73.57 ± 6.61% (TB 10nM), fig. 1a). 
There was no significant difference observed in coronary flow with all 3 concentrations when 
compared to the control group. Differences observed in LVDP were significant towards the 
end of the experimental protocol, at 160 mins. Both the 10 nM and 0.1 nM concentrations of 
Tiotropium bromide showed increased LVDP with respect to the control at 160 mins (100.11 
± 5.43% (10 nM) and 104.47 ± 1.19% (0.1 nM) vs. 83.19 ± 2.89% (control), fig. 1b). The 
LVDP at 160 mins was increased with respect to the 1 nM concentration of Tiotropium 
bromide (100.11 ± 5.43% (TB 10 nM) and 104.47 ± 1.19% (TB 0.1 nM) vs. 76.54 ± 6.11% 
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(TB 1nM), fig. 1b). There was no difference in heart rate amongst the treatment groups (fig. 
1c).    
 
Infarct sizes were calculated as a percentage of heart tissue found to be TTC negative. 
Administration of Tiotropium bromide (10 – 0.1 nM) saw increased infarct size compared to 
the control (fig.2). Tiotropium bromide (1 nM) showed the most increase in infarct size with 
respect to the control (18.69 ± 1.79% vs. 10.28 ± 1.74%, fig. 2). Both the 10 nM and 0.1 nM 
concentrations also showed increased infarct size of comparable magnitude, compared to 
the control (17.55 ± 0.98% (TB 10 nM) and 17.19 ± 0.37% (TB 0.1 nM) vs. 10.27 ± 1.94% 
(control),  fig. 2). 
 
Effect of KN-93 administration on whole heart haemodynamic function and infarct 
size. 
Administration of the CaMKII inhibitor, KN-93 (400 nM) alone or co-administered with 
Tiotropium bromide (1 nM) showed no significant effect on the coronary flow of the heart (fig. 
3a) and the heart rate (fig. 3c), however, significant differences were observed in LVDP. KN-
93, when co-administered with Tiotropium bromide, showed a significant increase in LVDP 
at 50 mins with respect to KN-93 alone (131.35 ± 12.62% (TB 1nM + KN-93 400nM) vs. 
91.75 ± 6.36% (KN-93 400nM), p<0.05, fig. 3b). This increase in LVDP following KN-93 and 
Tiotropium bromide co-administration was further observed at 160 mins with respect to all 
other treatment groups (103.47 ± 7.28% (TB 1nM + KN-93 400nM) vs. 83.19 ± 2.89% 
(control, p<0.05), 76.45 ± 6.11% (TB 1nM) and 77.14 ± 3.01% (KN-93 400nM), p<0.01, fig. 
3b).  
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KN-93 (400 nM) showed no significant difference in infarct size compared to the control, 
however this was significantly lower than that observed with Tiotropium bromide (1 nM) (9.50 
± 0.90% (KN-93 400nM) vs. 18.69 ± 1.79% (TB 1nM), p<0.01, fig. 4). This significance was 
sustained upon co-administration of KN-93 and Tiotropium bromide with respect to 
Tiotropium bromide alone, which showed reduced infarct development upon co-
administration (12.81 ± 2.81% (TB 1nM + KN-93 400nM) vs. 18.69 ± 1.79% (TB 1nM), 
p<0.05, fig. 4).  
 
Effect of Nifedipine on whole heart haemodynamic function and infarct size. 
The use of the L-type Ca2+ channel inhibitor, nifedipine (1 nM) in a whole heart Langendorff 
model showed a significant decrease in coronary flow when co-administered with Tiotropium 
bromide (1 nM), with respect to nifedipine (1 nM) alone both at 50 mins and at 70 mins (50 
minutes: 80.44 ± 6.02% (TB 1nM + Nif 1nM) vs. 99.98 ± 7.30% (Nif 1nM), p<0.05; 70 
minutes: 71.31 ± 8.83% (TB 1nM + Nif 1nM) vs. 98.98 ± 3.00% (Nif 1nM), p<0.01, fig. 5a). 
Administration of nifedipine did not show a significant difference in LVDP (fig. 5b) or heart 
rate (fig. 5c).  
 
Much like KN-93, nifedipine (1 nM) did not see a significant difference in infarct size 
compared to the control; however, nifedipine showed a significant decrease in infarct size 
when compared to Tiotropium bromide (1 nM) (6.32 ± 0.77% (Nif 1 nM) vs. 18.69 ± 1.79% 
(TB 1 nM), p<0.001, fig. 6). This significant decrease was also observed when Nifedipine 
was co-administered with Tiotropium bromide (11.32 ± 1.66% (TB 1 nM + Nif 1 nM) vs. 
18.69 ± 1.79% (TB 1 nM), p<0.01, fig. 6). 
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Effect of Tiotropium bromide on CaMKII phosphorylation in the presence and absence 
of KN-93. 
CaMKII activation was assessed using western blotting for phosphorylated CaMKII (Thr286) in 
cardiac tissue, to establish the role of CaMKII in Tiotropium bromide (1 nM) mediated 
cardiotoxicity, with or without the CaMKII inhibitor, KN-93 (400 nM). Tiotropium bromide 
showed a significant increase in CaMKII phosphorylation with respect to the control (86.46 ± 
8.43% (Tiotropium bromide 1 nM) vs. 43.73 ± 5.71% (control), fig. 7). The administration of 
KN-93 did not show any significant difference in CaMKII phosphorylation with respect to the 
control, however CaMKII phosphorylation with Tiotropium bromide was significantly greater 
than KN-93 alone (51.84 ± 8.11% (KN-93 400 nM) vs. 86.46 ± 8.43% (Tiotropium bromide 1 
nM), fig. 7). The increase in CaMKII phosphorylation observed with Tiotropium bromide was 
significantly attenuated when co-administered with KN-93, with respect to Tiotropium 
bromide alone (59.58 ± 8.94% (TB 1nM + KN-93 400nM) vs. 86.46 ± 8.43% (Tiotropium 
bromide 1nM), fig. 7). 
 
Effect of Tiotropium bromide on ventricular cardiomyocyte calcium release in the 
presence and absence of KN-93. 
Tiotropium bromide showed a significant increase in Fluo 3-AM fluorescence with respect to 
the control (130.63 ± 1.65% (TB 1nM) vs. 100 ± 0.0% (Control), p<0.05, fig. 8). Conversely, 
KN-93 did not show any significant difference in Fluo 3-AM fluorescence with respect to the 
control and Tiotropium bromide groups. The co-administration of KN-93 with Tiotropium 
bromide and Tiotropium bromide alone showed a significant increase in Fluo 3-AM with 
respect to the negative control, Amiloride (93.92 ± 10.01% (Amiloride 100 mM) vs. 130.63 ± 
1.65% (TB 1 nM) and 124.34 ± 22.30% (TB 1 nM + KN-93 400 nM), p<0.05, fig. 8). 
Ionomycin showed a significant increase in Fluo 3-AM fluorescence with respect to the 
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control and negative control, amiloride (135.69 ± 9.17% (Ionomycin 1 μM) vs. 100 ± 0.0% 
(Control) and 93.92 ± 10.01% (Amiloride 100 mM), p<0.01, fig. 8). 
 
 
Discussion 
The present study demonstrated that Tiotropium bromide altered calcium signalling, resulting 
in cell damage within the heart. Interestingly, the damage inflicted as a result of Tiotropium 
bromide administration had no effect on normal haemodynamic function. Additionally, this 
effect was attenuated through inhibition of L-type Ca2+ channels and CaMKII. 
Tiotropium bromide is a long acting muscarinic receptor antagonist with higher affinity for the 
M3 receptor subtype than the M2, functioning to inhibit cholinergic mediated 
bronchoconstriction within airway smooth muscle cells (Barnes et al., 2003). The M2 receptor 
subtype is known to be the predominant form in the heart, however M3 receptors are also 
present in the heart, and the function of these receptors has largely been attributed to 
pathological conditions such as ischaemia/reperfusion injury (Wang et al., 2012). The 
presence of muscarinic receptors in the heart has meant that adverse cardiovascular effect 
has always been a cause of concern for anti-muscarinics. Previous research has focused on 
the adverse cardiovascular effects associated with the short acting muscarinic receptor 
antagonist, Ipratropium bromide.  
However, recent studies have associated a link with increased cardiovascular events 
amongst COPD patients using anti-muscarinics such as Tiotropium bromide (Liou et al., 
2018; Arana et al., 2018; Koehorst-ter Huurne et al., 2018; Zou et al., 2018). Studies have 
assessed the use of Tiotropium bromide in comparison to β-adrenergic agonists and 
combination therapies; these meta-analyses have suggested that new use of long acting 
anti-muscarinics may be subjected to a greater risk of cardiovascular adverse effects (Wang 
et al., 2018). Although there have been discrepancies in the magnitude of cardiac effects 
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associated with anti-muscarinics (Wise et al., 2013), these studies corroborate with previous 
meta-analyses which suggest that Tiotropium bromide may affect cardiovascular risk 
amongst COPD patients (Singh et al., 2008; Singh et al., 2011). Interestingly, the data 
shown in this study proposes Ca
2+
 involvement in Tiotropium bromide mediated disturbances 
within the naïve heart, without significantly disrupting haemodynamic function, but affecting 
cell death as observed through exacerbated infarct size. A pilot study to measure cell death 
in cardiomyocytes with Tiotropium bromide was conducted using Annexin-V/PI staining. An 
increasing trend in apoptotic cells with increasing concentrations, however the 
concentrations used in this study (10 – 0.1 nM) did not show a significant increase in 
apoptosis [Supplementary File, S3].    
Ca2+ overload results in reversal of Na+/Ca2+ exchanger (NCX) function leading to increased 
intracellular Ca2+ release (Garcia-Dorado et al., 2012; Krebs et al., 2015). L-type Ca2+ 
channels mediate cellular calcium entry during excitation-coupling (Murgia & Rizzuto, 2014), 
leading to calcium induced calcium release (CICR); cardiotoxic drugs have been shown to 
increase intracellular Ca
2+
 (Hahn et al., 2014). Nifedipine is an L-type Ca
2+
 inhibitor; studies 
in isolated hearts have found nifedipine to reduce lactase dehydrogenase (LDH) leakage 
and neutrophil accumulation followi g myocardial ischaemia/reperfusion injury (Huang et al., 
2009). Nifedipine has negative inotropic and chronotropic effects but increases coronary flow 
at low concentrations (Kumar et al., 2012). In the present study, nifedipine significantly 
decreases infarct size, compared to Tiotropium bromide and co-administration abrogates 
Tiotropium bromide mediated infarct size. The protective effect of nifedipine on infarct size 
has been linked to nitric oxide (NO) production (Huang et al., 2009; Kitakaze et al., 2000). 
Co-administration of nifedipine with Tiotropium bromide also shows significant reduction in 
coronary flow. Muscarinic receptor activation has previously been associated with 
acetylcholine mediated vasoconstriction in rodent coronary vessels (Nasa et al., 1997), 
however the results of this study suggest that Tiotropium bromide induces vasoconstriction 
when administered with nifedipine despite the effect of nifedipine on NO. This suggests the 
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involvement of other Ca2+ mediators aside from L type Ca2+ channels in Tiotropium bromide 
mediated cardiotoxicity, as nifedipine administration dampens the effect of Tiotropium 
bromide on infarct size, but does not reverse it. 
A marked increase in CaMKII activity and abnormal Ca2+ release is observed in heart failure 
and arrhythmias (Fischer et al., 2013; Sossalla et al., 2010). M1, M3 and M5 receptors 
increase endoplasmic reticulum Ca
2+
 via phospholipase C (PLC), inositol 1,4,5 triphosphate 
(IP3) and calmodulin-dependent mechanisms (Pronin et al., 2017). CaMKII in 
ischaemia/reperfusion and myocardial infarction promotes cell death through mPTP opening 
and phosphorylation of ryanodine receptors (Di Carlo et al., 2014; Joiner et al., 2012). KN-93 
inhibition prevents calmodulin-CaMKII interaction and inhibits increases in sarcoplasmic 
reticulum (SR) Ca2+, leading to decreased excitation coupling (Zhang et al., 2004). However, 
KN-93 does not inhibit the catalytic activity of auto-phosphorylated CaMKII (Pellicena and 
Schulman 2014). KN-93 is good for assessing the function of CaMKII, however due to its 
competitive nature with calmodulin, autonomous activity can’t be inhibited, additionally, it 
also affects voltage gated K
+
 and Ca
2+
 channels (Ledoux, Chartier and Leblanc 1999, Vest 
et al. 2007). This study suggests that Tiotropium bromide increases CaMKII phosphorylation, 
which is attenuated but not fully reversed by KN-93, therefore suggesting auto-
phosphorylation of CaMKII. This study shows elevated Ca2+ in cardiomyocytes, through 
increased Fluo 3-AM fluorescence following Tiotropium bromide administration; this increase 
is attenuated with the use of KN-93 which suggests that CaMKII may be involved in 
Tiotropium bromide mediated Ca2+ release.  
CaMKII inhibition in addition to Tiotropium bromide shows enhanced LVDP function, but no 
other functional changes. Studies have shown that CaMKII inhibition in failing hearts 
improves contractility (Vila-Petroff et al., 2007); the data from this study suggests that 
inhibition of CaMKII improves LVDP function following Tiotropium bromide. As well as 
improvement in LVDP, there is also a protective effect observed with CaMKII inhibition of 
Tiotropium bromide mediated infarct size. Constitutive activation of ryanodine receptors by 
Journal Pre-proof
Jo
urn
al 
Pr
e-p
roo
f
CaMKII is known to increase cardiac injury (Di Carlo et al., 2014) and inhibition of CaMKII 
has been shown to decrease infarct size (Salas et al., 2010; Vila-Petroff et al., 2007). This 
study suggests that CaMKII inhibition may have beneficial effects on Tiotropium bromide 
mediated cardiac damage in naïve hearts.    
Few studies have evidenced pre-clinical data to assess the effect of muscarinic receptor 
antagonists on the heart. To our knowledge the only study which has observed the effect of 
anti-muscarinics in a cardiac model has shown Ipratropium bromide to exacerbate 
myocardial ischaemia/reperfusion injury via apoptotic mediators such as caspase-3 (Harvey 
et al., 2014). Tiotropium bromide has been described both as an inverse agonist (Kruse et 
al., 2012) and an antagonist (Cooke et al., 2015), our study suggests that Tiotropium 
bromide may exert an effect as an inverse agonist (figure 9), due to increased intracellular 
Ca2+ following Tiotropium bromide administration in cardiomyocytes, and increased infarct 
size compared to controls. M3 receptor activation leads to Gαq/1q-PLC mediated cleavage of 
phosphatidylinositol 4,5 bisphosphate (PIP2) into IP3 and diacylglycerol (DAG); IP3 in 
particular leads to sarcoplasmic reticulum calcium release via its receptor (IP3R) (Terrar et 
al., 2018). However further investigations are necessary to determine the role of Tiotropium 
bromide as an inverse agonist capable of eliciting a signalling effect in the heart.  
This study identifies dissociation between cardiac functional parameters and potentially 
detrimental cellular signalling, therefore highlighting a need for improved assessment of 
cardiotoxicity. Vascular biomarkers have recently been introduced in identifying at-risk 
populations amongst COPD patients, including aortic pulse wave velocity and intima media 
thickening, which have shown COPD to be an independent risk factor for cardiovascular 
disease (Fisk et al., 2018). The importance of translatable pre-clinical research cannot be 
emphasised enough, and it is vital to ensure that the effects observed in animal models are 
representative of in vivo signalling processes. This study has shown the effects of Tiotropium 
bromide in naïve conditions, finding detectable changes in cardiac damage in a Ca2+ 
mediated manner.  
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This is the first pre-clinical study to show that Tiotropium bromide alters calcium signalling in 
the heart through modulation of intracellular calcium release and enhanced activation of the 
Ca2+/Calmodulin dependent protein kinase II (CaMKII) in naïve hearts, without significantly 
affecting haemodynamic function.  
The results of this study have considerable impact on clinical decision making, particularly 
regarding COPD patients who are at greater risk of cardiovascular complications. Whilst 
COPD itself is a risk factor for cardiovascular disease, the use of drugs, which may elevate 
this risk without significantly altering cardiovascular function, raises an urgent need to 
identify and screen for changes occurring at a cellular level, prior to major cardiovascular 
remodelling which may affect haemodynamic function.    
In conclusion, this study provides evidence that intracellular Ca2+ signalling follows 
Tiotropium bromide administration in cardiac models. The pharmacological inhibition of 
CaMKII and L-type Ca2+ channels show protective effects on Tiotropium bromide mediated 
cardiac injury and therefore warrants further investigation of the cellular processes 
underlying these effects. It is necessary to implement changes to how COPD patients are 
assessed for adverse cardiovascular effects, in order to precipitate the cellular changes 
which may be occurring as a result of off-target drug effects. 
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Figure 1. The effect of Tiotropium bromide (10 – 0.1 nM) on the haemodynamic function of 
the heart. A) Tiotropium bromide effect on coronary flow, B) LVDP and C) Heart rate as a 
percentage of the mean stabilisation period. * p<0.05 vs. time matched control, # p<0.05 
Tiotropium bromide (0.1 nM) vs. Tiotropium bromide (10 nM), ## p<0.01 Tiotropium bromide 
(1 nM) vs. Tiotropium bromide (10 nM), $$ Tiotropium bromide (1 nM) vs. Tiotropium 
bromide (0.1 nM) n = 3-5. BPM, beats per minute.  
 
 
Figure 2. The effect of Tiotropium bromide (10 – 0.1 nM) on infarct size in the whole heart 
Langendorff model. ** p<0.01 vs. Control, and *** p<0.001 vs. Control, n = 3-5.  
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Figure 3. The effect of Tiotropium bromide (1 nM) ± KN-93 (400 nM) on the haemodynamic 
function of the heart. A) Tiotropium bromide ± KN-93 effect on coronary flow, B) LVDP and 
C) Heart rate as a percentage of the mean stabilisation period. * p<0.05 vs. time matched 
control, ## p<0.01 TB (1 nM) + KN-93 (400 nM) vs. Tiotropium bromide (1 nM), $ p<0.05 TB 
(1 nM) + KN-93 (400 nM) vs. KN-93 (400 nM) and $$ p<0.01 TB (1 nM) + KN-93 (400 nM) 
vs KN-93 (400 nM) n = 4-5. BPM, beats per minute, TB, Tiotropium bromide. 
 
 
Figure 4. The effect of Tiotropium bromide (1 nM) ± KN-93 (400 nM) on infarct size in the 
whole heart Langendorff model. *** p<0.001 vs. Control, # p<0.05 vs. Tiotropium bromide (1 
nM), ## p<0.01 vs. Tiotropium bromide (1 nM), n = 4-5. TB, Tiotropium bromide. 
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Figure 5. The effect of Tiotropium bromide (1 nM) ± Nifedipine (1 nM) on the haemodynamic 
function of the heart. A) Tiotropium bromide ± Nifedipine effect on coronary flow, B) LVDP 
and C) Heart rate as a percentage of the mean stabilisation period. $ p<0.05 TB (1 nM) + Nif 
(1 nM) vs. Nif (1 nM) and $$ p<0.01 TB (1 nM) + Nif (1 nM) vs. Nif (1 nM) n = 4-5. BPM, 
beats per minute, TB, Tiotropium bromide, Nif, Nifedipine. 
 
 
Figure 6. The effect of Tiotropium bromide (1 nM) ± Nifedipine (1 nM) on infarct size in the 
whole heart Langendorff model. *** p<0.001 vs. Control, ## p<0.01 vs. Tiotropium bromide 
(1 nM), ### p<0.001 vs. Tiotropium bromide (1 nM), n = 4-5. TB, Tiotropium bromide, Nif, 
Nifedipine. 
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Figure 7. The effect of Tiotropium bromide (1 nM) ± KN-93 (400 nM) on expression of 
phosphorylated cardiac CaMKII. *** p<0.001 vs. Control, # p<0.05 vs. Tiotropium bromide (1 
nM), ## p<0.01 vs. Tiotropium bromide (1 nM), n = 3. TB, Tiotropium bromide. 
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Figure 8. Calcium release as determined with Fluo 3-AM fluorescence following Tiotropium 
bromide (1 nM) ± KN-93 (400 nM) in cardiomyocytes. * p<0.05 vs. Control, ** p<0.01 vs. 
Control, # p<0.05 vs. TB (1 nM), $ p<0.05 vs. TB (1 nM) + KN-93 (400 nM), € vs. p<0.05 vs. 
Amiloride (100 mM), n = 3-6. TB, Tiotropium bromide. 
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Figure 9. A schematic illustrating the proposed effect of Tiotropium bromide administration 
in cardiomyocytes. Tiotropium bromide may exert an inverse agonist function and trigger 
calcium signalling through Gq/11 mediated phospholipase C (PLC) signalling releasing 
sarcoplasmic reticulum (SR) Ca2+ into the cell. PIP2, phosphatidylinositol 4,5 bisphosphate; 
IP3, inositol 1,4,5 triphosphate; DAG, diacylglycerol; M3, muscarinic receptor subtype 3; 
IP3R, inositol 1,4,5 triphosphate receptor. Created using BioRender software. 
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Highlights: 
 Anti-muscarinics have been associated with increased cardiovascular risk in chronic 
obstructive pulmonary disease (COPD). 
 Tiotropium bromide results in detrimental calcium signalling in whole heart models, 
observed with increased infarction. 
 The effects of Tiotropium bromide are reversed with L-type Ca2+ channel and CaMKII 
inhibitors. 
 Anti-muscarinics such as Tiotropium bromide may result in adverse cardiac effects without 
affecting cardiac function.   
 Further tests should be used to monitor COPD patients using anti-muscarinics for adverse 
cardiovascular effects. 
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